EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
EMA’s safety committee (
PRAC
) has recommended measures to minimise the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders. These side effects include cardiovascular conditions, blood clots, cancer and serious infections.
The Committee recommended that these medicines should be used in the following patients only if no suitable treatment alternatives are available: those aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer.
The Committee also recommended using JAK inhibitors with caution in patients with risk factors for blood clots in the lungs and in deep veins (venous thromboembolism, VTE) other than those listed above. Further, the doses should be reduced in some patient groups who may be at risk of VTE, cancer or major cardiovascular problems.
The recommendations follow a review of available data, including the final results from a
clinical trial
1
of the JAK inhibitor Xeljanz (tofacitinib) and preliminary findings from an observational study involving Olumiant (baricitinib), another JAK inhibitor. During the review, the
PRAC
sought advice from an expert group of rheumatologists, dermatologists, gastroenterologists and patient representatives.
The review confirmed Xeljanz increases the risk of major cardiovascular problems, cancer, VTE, serious infections and death due to any cause when compared with TNF-alpha inhibitors. The
PRAC
has now concluded that these safety findings apply to all approved uses of JAK inhibitors in chronic inflammatory disorders (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, ulcerative colitis, atopic dermatitis and alopecia areata).
The
product information
for JAK inhibitors used to treat chronic inflammatory disorders will be updated with the new recommendations and warnings. In addition, the educational material for patients and healthcare professionals will be revised accordingly. Patients who have questions about their treatment or their risk of serious side effects should contact their doctor.
More information is available in
EMA’s public health communication
.
EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines
The
PRAC
has confirmed its recommendation to withdraw the
marketing authorisations
for amfepramone obesity medicines. This follows a
re-examination
of its
previous recommendation
of June 2022, which was requested by the companies that market these medicines.
The recommendation follows a review which found that measures to restrict the use of these medicines for safety reasons have not been sufficiently effective. It found that the medicines were being used for longer than the recommended maximum period of 3 months, thereby potentially increasing the risk of serious side effects, such as pulmonary arterial hypertension (high blood pressure in the lungs) and dependency. The medicines were also being used in patients with a history of heart disease or psychiatric disorders, increasing their risk of heart and psychiatric problems. In addition, there was evidence of use during pregnancy, which could pose risks to the unborn baby.
The review considered all available information relating to these concerns, including data from two studies on the use of amfepramone medicines in Germany and in Denmark. In addition, the
PRAC
received advice from a group of experts, comprising endocrinologists, cardiologists and a patient representative.
The
PRAC
considered introducing further measures to minimise the risk of side effects but could not identify any that would be sufficiently effective. The
PRAC
therefore concluded that the benefits of amfepramone medicines do not outweigh their risks and recommended that the medicines be removed from the market in the EU.
The
PRAC
recommendation will now be sent to the
CMDh
2
for its consideration.
More information is available in
EMA’s public health communication
.
Comirnaty and Spikevax: heavy menstrual bleeding added as a side effect
The
PRAC
has recommended that heavy menstrual bleeding should be added to the
product information
as a side effect of unknown frequency of the mRNA COVID-19 vaccines Comirnaty and Spikevax.
Heavy menstrual bleeding (heavy periods) may be defined as bleeding characterised by an increased volume and/or duration which interferes with the person’s physical, social, emotional and material quality of life. Cases of heavy menstrual bleeding have been reported after the first, second and booster doses of Comirnaty and Spikevax.
The
PRAC
finalised the assessment of this
safety signal
after reviewing the available data, including cases reported during
clinical trials
, cases spontaneously reported in
Eudravigilance
and findings from the medical literature.
After reviewing the data, the Committee concluded that there is at least a reasonable possibility that the occurrence of heavy menstrual bleeding is causally associated with these vaccines and therefore recommended the update of the
product information
.
The available data reviewed involved mostly cases which appeared to be non-serious and temporary in nature.
Menstrual disorders in general are quite common and they can occur for a wide range of reasons. This includes some underlying medical conditions. Any person who experiences postmenopausal bleeding or is concerned about a change in menstruation should consult their doctor.
There is no evidence to suggest the menstrual disorders experienced by some people have any impact on reproduction and fertility. Available data provides reassurance about the use of mRNA COVID-19 vaccines before and during pregnancy.
A review
carried out by EMA’s Emergency Task Force showed that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, and they are as effective at reducing the risk of hospitalisation and deaths in pregnant people as they are in non-pregnant people.
The Committee reiterates that the totality of data available confirms that the benefits of these vaccines greatly outweigh the risks.
Healthcare professionals and patients are encouraged to continue to report cases of heavy menstrual bleeding to their national authorities.
The
PRAC
will continue to monitor for cases of this condition and will communicate further if new recommendations are warranted.
Ustekinumab (Stelara): warning on use of live vaccines in infants whose mothers received ustekinumab during pregnancy
The
PRAC
has recommended adding a warning to the
product information
for ustekinumab (Stelara) on the use of live vaccines in infants whose mothers received ustekinumab during their pregnancy.
Ustekinumab
is authorised in the European Union to treat severe plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
The
product information
already advises that it is preferable to avoid use of ustekinumab during pregnancy. People of childbearing potential are advised to avoid becoming pregnant and must use adequate contraception while using Stelara and for at least 15 weeks after the last Stelara treatment.
The Committee has reviewed the available evidence regarding use of ustekinumab during pregnancy, including observational studies from the EU, United States and Canada, as well as a cumulative review requested from the
marketing authorisation holder
.
Ustekinumab can cross the placenta. It has been detected in the serum (the fluid component of the blood) of infants who were exposed to ustekinumab in utero (infants whose mothers were treated with the medicine during pregnancy).
Although the data on ustekinumab are limited, the risk of infection may be increased after birth in infants who were exposed to ustekinumab in utero.
Therefore, the
PRAC
recommended that, in infants who were exposed to ustekinumab in utero, the administration of live vaccines (vaccines made from a virus or bacterium that has been weakened) is not recommended for six months following birth or until the infant’s serum levels of ustekinumab are undetectable. In case of a clear clinical benefit for the individual infant, administration of a live vaccine might be considered earlier, if the infant’s serum levels of ustekinumab are undetectable.
The
PRAC
’s recommendation will be forwarded to EMA’s human medicines committee (
CHMP
) for adoption.
New safety information for healthcare professionals
As part of its advice on safety-related aspects to other EMA committees, the
PRAC
discussed direct healthcare professional communications (DHPCs) containing important information for Janus kinase (JAK) inhibitors and amfepramone medicines.
Janus kinase (JAK) inhibitors: measures to minimise risk of serious side effects
This DHPC will inform healthcare professionals about the risk minimisation measures for certain serious side effects associated with Janus kinase (JAK) inhibitors used in chronic inflammatory disorders.
Amfepramone medicines: advice to patients about other treatment options
This DHPC will inform healthcare professionals on the conclusion of the
re-examination
of EMA’s recommendation on amfepramone-containing medicines and on the need to advise patients about other treatment options.
The DHPC for amfepramone medicines will be forwarded to the Coordination Group for
Mutual Recognition
and
Decentralised Procedures
– Human (
CMDh
) and the DHPC for Janus kinase inhibitors will be forwarded to EMA’s human medicines committee (
CHMP
). Following the CHMDh and
CHMP
opinion, the DHPCs will be disseminated to healthcare professionals by the
marketing authorisation holder
, according to an agreed communication plan, and published on the ‘
Direct healthcare professional communications
’ page and in
national registers
in EU Member States.
1
Ytterberg SR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.
New Engl J Med
2022;
3
86(4):316-326. doi:
10.1056/NEJMoa2109927
2
Co-ordination Group for
Mutual Recognition
and
Decentralised Procedures
- Human
Agenda
List item
Agenda of the PRAC meeting 24-27 October 2022
(PDF/431.23 KB)
(new)
Draft
First published: 24/10/2022
EMA/785930/2022
PRAC statistics: November 2022
List item
PRAC statistics: November 2022
(PDF/542.81 KB)
(new)
First published: 28/10/2022
Glossary:
Safety signal
assessments
. A
safety signal
is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine and an
adverse event
that warrants further investigation.
Safety signals
are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under '
Signal management
'.
Periodic safety update reports
, abbreviated as PSURs, are reports prepared by the
marketing authorisation holder
to describe the worldwide safety experience with a medicine in a defined period after its authorisation. PSURs for
medicinal products
that contain the same
active substance
or the same combination of
active substances
but have different
marketing authorisations
and are authorised in different EU Member States, are jointly assessed in a single assessment procedure. More information can be found under '
Periodic safety update reports: questions and answers
'.
Risk management plans
, abbreviated as RMPs, are detailed descriptions of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Companies are required to submit an RMP to EMA when applying for a
marketing authorisation
. RMPs are continually updated throughout the lifetime of the medicine as new information becomes available. More information is available under
'Risk-management plans
'.
Post-authorisation safety studies
, abbreviated as PASSs, are studies carried out after a medicine has been authorised to obtain further information on its safety, or to measure the effectiveness of risk-management measures. The
PRAC
assesses the protocols (aspects related to the organisation of a study) and the results of PASSs. More information can be found under '
Post-authorisation safety studies
'.
Referrals
are procedures used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a
referral
related to safety of medicines, the
PRAC
is requested by a Member State or the European Commission to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. More information can be found under
referral procedures
.
Summary safety reports
have been introduced as part of the enhanced safety monitoring of COVID-19 vaccines.
Marketing authorisation holders
are required to submit these reports to EMA, starting on a monthly basis. Their submission complements the submission of PSURs. For more information see
EMA’s pharmacovigilance plan for COVID-19 vaccines
.
